Masimo (NASDAQ:MASI) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding ...

Masimo (MASI) stock is drawing fresh attention after the company received FDA 510(k) clearance for its pediatric Patient State Index sedation score, a first-of-its-kind tool tailored to children’s ...

Remote and continuous patient monitoring is moving from a niche capability to a core pillar of modern healthcare, driven by aging populations, staffing shortages, and a push toward data-driven care ...

Masimo Corporation MASI is well-poised for growth in the coming quarters, courtesy of its strong underlying demand for innovative technology and research and development (R&D) efforts. The optimism, ...

Masimo stock jumped 34% after The Wall Street Journal reported that life-sciences conglomerate Danaher was nearing a $10 billion deal to buy the medical-device maker. Danaher shares were down over 6%.

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Masimo (MASI) has drawn fresh investor attention after ...

This was a full sale; Masimo now represents 0% of the fund's reported 13F AUM Top holdings after the filing: NASDAQ: APEI: $10,459,550 (5.5685% of AUM) NYSE: TPB: $9,886,000 (5.2632% of AUM) NYSE: ...

Masimo shares rocketed after biotech conglomerate Danaher struck a deal to acquire the medical-device maker for almost $10 billion. Masimo shares (MASI) surged by roughly one-third Tuesday morning to ...

A federal judge upheld Masimo’s $643 million patent victory over Apple, rejecting the tech giant’s latest attempt to overturn ...